Key Drivers
- High liquidity
- Deep losses
- Rising leverage
AIAI Summary
Precigen's transition to a commercial-stage company makes PAPZIMEOS uptake and payer reimbursement — not clinical risk — the determinant of equity value, so investors should closely monitor March 25 results, monthly hub enrollments, and real-world reimbursement levels as binary execution triggers that will dictate whether rising debt forces dilutive financing or enables a sustainable revenue-backed path to break-even.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High liquidity
- •Deep losses
- •Rising leverage
PGEN shows strong short-term liquidity and large investment/tangible assets but is marked by severe cash burn, widening operating losses, and a sharp spike in debt that undermines solvency.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Lower lows
- •Momentum bias
PGEN has trended sharply lower over the last month, falling ~26% from $4.74 to $3.51 with a 37% drop from the Feb 17 peak to the Mar 12 low, signaling clear downside momentum unless buyers push it back above $4.00–$4.20 or sustain a move above ~$4.40–$4.75.
37% fall from $5.21 peak to $3.28 low over the period
Sentiment & News
Key News Insights:
- •Mixed analyst sentiment
- •March 25 catalyst
- •Commercial-stage status
Precigen faces split analyst ratings (2 sell, 1 hold, 4 buy) and heightened market focus ahead of its March 25 release of full‑year 2025 results and a 2026 business update.
The March 25 disclosure is likely to drive near‑term share volatility as investors seek clarity on recent performance and strategic direction
Similar Companies in Healthcare
Other companies in the same sector with AI ratings